Researchers at UC Davis have engineered a new class of compounds that activate the same brain receptors targeted by psychedelics, yet produce none of the hallucinations. The breakthrough could reshape treatment for depression, PTSD, and addiction by delivering therapeutic benefits without the perceptual distortions.
The team used ultraviolet light to transform amino acids into molecules that mimic psychedelics' effects on the brain. Specifically, they combined amino acids with tryptamine, a metabolite derived from tryptophan, then exposed the mixture to UV radiation. The chemical reaction generated entirely novel compounds with potential medical applications.
Computer modeling narrowed down more than 100 candidates to five compounds for laboratory testing. The strongest performer, called D5, acted as a full agonist on the serotonin 5-HT2A receptor, meaning it triggered the maximum possible biological response from that receptor system.
The crucial test came in mice. Scientists expected D5 to produce head twitch responses, a standard marker for hallucinogenic-like behavior in animal studies. It did not. Despite fully activating the same receptor that traditional psychedelics target, D5 suppressed psychedelic-like responses entirely.
"The question we were trying to answer was, 'Is there a whole new class of drugs in this field that hasn't been discovered?'" said Joseph Beckett, the Ph.D. student leading the work under Professor Mark Mascal in UC Davis's Department of Chemistry. "The answer was, yes."
Trey Brasher, another Ph.D. student involved in the research, emphasized the rarity of the discovery. "In medicinal chemistry, we typically tweak existing drug structures slightly," Brasher said. "But completely new scaffolds are incredibly rare. This is a brand-new therapeutic scaffold."
The findings were published in the Journal of the American Chemical Society. The work opens the door to a more efficient and environmentally sustainable approach for discovering serotonin-targeting medications that harness psychedelics' brain-healing properties without fundamentally altering perception.
Researchers now plan to investigate why D5 and related molecules escape hallucinogenic effects despite full receptor activation. The team suspects other serotonin receptors may be blocking or suppressing the perceptual side effects. Understanding this mechanism could be key to developing an entire new family of non-hallucinogenic psychiatric treatments.
Author Jessica Williams: "This is the kind of basic science that could genuinely change how we treat mental illness, and the fact that they did it without sacrificing the therapeutic punch is a genuine win."
Comments